IDiyas

For the Inventor, By the Inventor

Munich, Germany

Sebastian Fenn

USPTO Granted Patents = 11 

Average Co-Inventor Count = 5.5

ph-index = 3

Forward Citations = 21(Granted Patents)


Location History:

  • Achmuhle/Eurasburg, GB (2019)
  • Munich, DE (2018 - 2022)
  • Penzberg, DE (2023)
  • Achmuehle/Eurasburg, DE (2021 - 2024)

Company Filing History:

goldMedal10 out of 4,942 
 
Hoffmann-la Roche Inc.
 patents
where one patent can have more than one assignee

Years Active: 2018-2024

Loading Chart...
11 patents (USPTO):
1. 12157770 - Anti-HLA-G antibodies and methods of use thereof (2024-12-03),
2. 12030952 - Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use (2024-07-09),
3. 11820816 - Anti-VEGF antibodies and methods of use (2023-11-21),
4. 11787868 - Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use (2023-10-17),
5. 11732036 - Antibody that binds to VEGF-A and ANG2 and methods of use (2023-08-22),
6. 11603411 - Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use (2023-03-14),
7. 11421022 - Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof (2022-08-23),
8. 11407836 - Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof (2022-08-09),
9. 10941205 - Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use (2021-03-09),
10. 10434184 - Anti-TPBG antibodies and methods of use (2019-10-08),
11. 10106612 - Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof (2018-10-23),

Title: The Innovative Mind of Sebastian Fenn: Pioneering Antibody Technologies

Introduction

Sebastian Fenn, an accomplished inventor based in Munich, Germany, has made significant contributions to the field of biotechnology. He holds an impressive portfolio of 11 patents, showcasing his innovative spirit and dedication to advancing medical science.

Latest Patents

Among his notable inventions are two recent patents that display his expertise in the development of therapeutic antibodies. The first, titled "Anti-HLA-G antibodies and methods of use thereof," relates to the creation of anti-HLA-G antibodies and outlines various methodologies for their application. The second patent, "Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use," describes bispecific antibodies that target both human CD20 and the human transferrin receptor, along with the methods for utilizing these novel therapeutics.

Career Highlights

Sebastian Fenn is currently associated with Hoffmann-La Roche Inc., a global leader in pharmaceuticals and diagnostics. His work at the company has allowed him to focus on cutting-edge research and development, contributing to groundbreaking advancements in immunology and cancer therapies.

Collaborations

In his career, Fenn has collaborated with talented professionals such as Sabine Imhof-Jung and Michael Molhoj. These partnerships enhance the innovative process, allowing for the exchange of ideas and the development of new technologies that can lead to significant medical breakthroughs.

Conclusion

Sebastian Fenn exemplifies the spirit of innovation within the biotechnology sector. With his extensive patent portfolio and impactful collaborations, he continues to push the boundaries of science, paving the way for new therapies that can improve patient outcomes. His commitment to research and development is a testament to the potential of inventors in shaping the future of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…